Bufotalin, an active component of Venenum bufonis, has long been used as an anti-tumor drug in China and has proven anti-tumor effects in cancer types. In the following study, researchers use MTT and colony formation assays to analyze the effects of bufotalin on A375 melanoma cells. Results show that bufotalin induces A375 cell cycle arrest at the G2/M phase by up-regulating and down-regulating specific protein expressions. Furthermore, bufotalin up-regulates apoptosis-related proteins, in turn inducing A375 cell apoptosis. These results indicate that bufotalin may prove effective in melanoma treatment. [LINK]
An A375 Transfection Reagent is commercially available from Altogen Biosystems, which includes standard and reverse protocols to transfect A375 cells. A xenograft model of this cell line can be found here.
An A375 Transfection Reagent is commercially available from Altogen Biosystems, which includes standard and reverse protocols to transfect A375 cells. A xenograft model of this cell line can be found here.
Comments
Post a Comment